Literature DB >> 18195267

Elevated plasma homocysteine levels in patients with amyotrophic lateral sclerosis.

S Zoccolella1, I L Simone, P Lamberti, V Samarelli, R Tortelli, L Serlenga, G Logroscino.   

Abstract

BACKGROUND: Both in vitro and in vivo studies indicate that homocysteine (Hcy) may be directly involved in the damage of motor neurons and in several pathways implicated in amyotrophic lateral sclerosis (ALS) pathogenesis.
OBJECTIVE: To determine whether plasma Hcy levels were higher in ALS patients than healthy controls and to examine the relationship between Hcy levels and clinical ALS phenotypes.
METHODS: In a cross-sectional study, we compared Hcy, B(12), and folate levels in 62 patients with ALS and 88 age- and sex-matched controls recruited as outpatients in a tertiary clinical center.
RESULTS: Patients with ALS had higher median plasma Hcy levels (11.2 [range 5.8 to 46] vs 9.7 [range 4.5 to 15.9] micromol/L; p = 0.0004) and lower folate levels (4.4 [range 1.7 to 22.1] vs 5.8 [range 2.3 to 21.1] ng/mL; p = 0.0003), compared with controls. Multivariate logistic regression revealed a strong direct association between plasma Hcy levels and presence of ALS (odds ratios adjusted for age, sex, and B-vitamin levels comparing the top tertile [Hcy levels >or= 11.6 micromol/L] with the bottom tertile [Hcy levels < 9.2 micromol/L]: 6.4; 95% CI 2.2 to 19.1; p for trend = 0.0008). We also found a trend for higher Hcy levels in patients with shorter interval from symptom onset to diagnosis (ODI; <14 months), compared with patients with longer ODI (>14 months; median Hcy levels 11.8 [range 5.8 to 46] vs 10.1 [range 7.2 to 17.6] micromol/L; p = 0.09). In a multivariate model, Hcy levels strongly correlated with shorter interval onset diagnosis (r(2) = 0.18; p = 0.01).
CONCLUSIONS: Plasma homocysteine (Hcy) levels were significantly increased in patients with amyotrophic lateral sclerosis (ALS) compared with healthy controls. ALS cases with shorter time to diagnosis presented higher Hcy levels, suggesting that higher Hcy may be linked to faster progression of the disease.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18195267     DOI: 10.1212/01.wnl.0000297193.53986.6f

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  17 in total

Review 1.  Complementary and Alternative Therapies in Amyotrophic Lateral Sclerosis.

Authors:  Richard S Bedlack; Nanette Joyce; Gregory T Carter; Sabrina Paganoni; Chafic Karam
Journal:  Neurol Clin       Date:  2015-09-08       Impact factor: 3.806

2.  Are plasma homocysteine and methionine elevated when binging and purging behavior complicates anorexia nervosa? Evidence against the transdiagnostic theory of eating disorders.

Authors:  S M Innis; C L Birmingham; E J Harbottle
Journal:  Eat Weight Disord       Date:  2009-12       Impact factor: 4.652

3.  Elevated plasma homocysteine levels in patients with multiple sclerosis are associated with male gender.

Authors:  Stefano Zoccolella; Carla Tortorella; Pietro Iaffaldano; Vita Direnzo; Mariangela D'Onghia; Damiano Paolicelli; Paolo Livrea; Maria Trojano
Journal:  J Neurol       Date:  2012-03-16       Impact factor: 4.849

4.  Hypolipidemia in patients with amyotrophic lateral sclerosis: a possible gender difference?

Authors:  Ji Won Yang; Sung-Min Kim; Hee-Juang Kim; Jee-Eun Kim; Kyung Seok Park; Seung-Hyun Kim; Kwang-Woo Lee; Jung-Joon Sung
Journal:  J Clin Neurol       Date:  2013-04-04       Impact factor: 3.077

5.  Efficacy and Safety of Ultrahigh-Dose Methylcobalamin in Early-Stage Amyotrophic Lateral Sclerosis: A Randomized Clinical Trial.

Authors:  Ryosuke Oki; Yuishin Izumi; Koji Fujita; Ryosuke Miyamoto; Hiroyuki Nodera; Yasutaka Sato; Satoshi Sakaguchi; Hiroshi Nokihara; Kazuaki Kanai; Taiji Tsunemi; Nobutaka Hattori; Yuki Hatanaka; Masahiro Sonoo; Naoki Atsuta; Gen Sobue; Toshio Shimizu; Kazumoto Shibuya; Ken Ikeda; Osamu Kano; Kazuto Nishinaka; Yasuhiro Kojima; Masaya Oda; Kiyonobu Komai; Hitoshi Kikuchi; Nobuo Kohara; Makoto Urushitani; Yoshiaki Nakayama; Hidefumi Ito; Makiko Nagai; Kazutoshi Nishiyama; Daisuke Kuzume; Shun Shimohama; Takayoshi Shimohata; Koji Abe; Tomohiko Ishihara; Osamu Onodera; Sagiri Isose; Nobuyuki Araki; Mitsuya Morita; Kazuyuki Noda; Tatsushi Toda; Hirofumi Maruyama; Hirokazu Furuya; Satoshi Teramukai; Tatsuo Kagimura; Kensuke Noma; Hiroaki Yanagawa; Satoshi Kuwabara; Ryuji Kaji
Journal:  JAMA Neurol       Date:  2022-06-01       Impact factor: 29.907

Review 6.  Nutrition and dietary supplements in motor neuron disease.

Authors:  Jeffrey Rosenfeld; Amy Ellis
Journal:  Phys Med Rehabil Clin N Am       Date:  2008-08       Impact factor: 1.784

Review 7.  Palliative Care Issues in Amyotrophic Lateral Sclerosis: An Evidenced-Based Review.

Authors:  Chafic Y Karam; Sabrina Paganoni; Nanette Joyce; Gregory T Carter; Richard Bedlack
Journal:  Am J Hosp Palliat Care       Date:  2014-09-08       Impact factor: 2.500

8.  Disease-related changes in the cerebrospinal fluid metabolome in amyotrophic lateral sclerosis detected by GC/TOFMS.

Authors:  Anna Wuolikainen; Thomas Moritz; Stefan L Marklund; Henrik Antti; Peter Munch Andersen
Journal:  PLoS One       Date:  2011-04-04       Impact factor: 3.240

9.  Plasma Total Homocysteine Levels are not Associated with Medial Temporal Lobe Atrophy, but with White Matter Changes in Alzheimer's Disease.

Authors:  Sung Rae Kim; Seong Hye Choi; Choong Kun Ha; Shin Goo Park; Hae Wook Pyun; Dae Hyun Yoon
Journal:  J Clin Neurol       Date:  2009-06-30       Impact factor: 3.077

10.  Transcriptome Profiling Following Neuronal and Glial Expression of ALS-Linked SOD1 in Drosophila.

Authors:  Emily L Kumimoto; Taylor R Fore; Bing Zhang
Journal:  G3 (Bethesda)       Date:  2013-04-09       Impact factor: 3.154

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.